NeuroOne Medical Technologies Corporation — FY 2017 Form 10-K
Reporting period: Fiscal year ended December 31, 2017. The filing was signed April 16, 2018. NeuroOne acquired the operating business in July 2017; the financial statements principally reflect NeuroOne and its predecessor, not the former public shell. The 2017 results are therefore not fully comparable with the combined 2016 periods.
Business context and outlook
NeuroOne is an early-stage medical technology company developing thin-film cortical and depth electrodes for brain-signal recording, with planned stimulation and ablation applications. It had no approved products and no product revenue in 2017. Its initial target is epilepsy diagnosis in the United States.
Management planned to complete testing and submit a 510(k) application for cortical strip and grid electrodes in 2018, with a potential U.S. launch late in 2018 if cleared. Diagnostic depth electrodes were targeted for a 510(k) submission in early 2019. These are plans, not assured milestones; the therapeutic applications may require clinical studies and a more extensive approval pathway.
Financial performance and position
| Metric | FY 2017 / Dec. 31, 2017 | FY 2016 comparison |
|---|---|---|
| Revenue | $0 | $0 |
| General and administrative expense | $2.337 million | $0.189 million combined |
| Research and development expense | $0.735 million | $0 |
| Total operating expenses / operating loss | $3.072 million | $0.189 million combined |
| Interest expense | $1.395 million | $0.095 million combined |
| Net loss | $5.058 million | $0.285 million combined |
| Net loss per share | $0.77 | $0.06 for successor period |
| Net cash used in operating activities | $2.108 million | $0.176 million for successor period |
| Net cash from financing activities | $1.704 million | $0.698 million for successor period |
Revenue and gross margin are not applicable because the company had no product sales. Operating expenses rose by $2.883 million year over year on the filing’s combined comparison, principally from added personnel, legal and accounting costs, and development spending. Interest expense increased with additional debt and debt-discount amortization. The company also recorded a $0.351 million noncash extinguishment loss on amended notes and a $0.240 million net fair-value expense for warrant and conversion derivative liabilities.
At year-end, cash was $26,467, current assets were $33,613, total assets were $249,985, current liabilities were $3.905 million, total liabilities were $5.287 million, and stockholders’ deficit was $5.037 million. Accumulated deficit was $5.325 million. The balance sheet included $1.381 million of warrant liability and $0.462 million of premium conversion derivative liability.
Liquidity, debt and material changes
The auditor and management stated that recurring losses, negative operating cash flow and inadequate liquidity raise substantial doubt about the company’s ability to continue as a going concern. Management said year-end cash would not fund 2018 operations and additional financing was necessary. No committed external funding source was disclosed.
As of March 31, 2018, principal and accrued interest on outstanding notes totaled approximately $3.190 million: Series 1, $1.771 million; Series 2, $0.254 million; and Series 3, $1.167 million. Series 1 and Series 2 were due July 31, 2018 unless qualifying financings occurred; Series 3 was due December 31, 2018 unless its financing condition was met. The filing states the company would not have sufficient cash to repay the Series 1 and Series 2 notes if they became due. Note conversions and warrant terms may also result in significant dilution.
2017 financing cash inflows did not offset operating cash use and investing outflows; cash fell from $522,217 at the end of 2016 to $26,467 at the end of 2017. Subsequent to year-end, the company reported issuing an additional $475,000 of Series 3 notes and receiving a $115,000 interest-free stockholder loan in March 2018.
Risks, contingencies and unusual items
- Development and regulatory risk: The technology had only limited research use, including testing in a small number of patients, and had not been tested in company-sponsored clinical trials or cleared for sale. Timelines, regulatory classification and required clinical evidence remained uncertain.
- Financing and going concern: The company expects continuing losses and requires substantial additional capital. Failure to raise funds or refinance debt could force it to delay development, curtail operations or liquidate assets.
- Material weaknesses: Management concluded financial reporting controls were ineffective, citing weaknesses in complex debt and equity accounting, the close and reporting process, routine transaction controls and segregation of duties. Remediation could be delayed by limited cash.
- Litigation: PMT Corp. filed suit on March 29, 2018 against the company, its subsidiary and an officer, alleging restrictive-covenant, trade-secret and related claims. The company said it intended to defend the case; outcome and potential loss were unknown. The company disclosed no insurance coverage for this claim.
- Licenses and commitments: The company had previously breached provisions of its WARF and Mayo agreements, later amended or cured as described in the filing. A $55,000 WARF license fee became due May 3, 2018; future minimum royalties begin in 2019 if the license remains in effect. Loss of either research relationship could impair development.
- Other risks: Reliance on third-party manufacturers, stronger established competitors, uncertain reimbursement and market adoption, limited intellectual-property protection, and a thinly traded OTC market. The filing also reported no general, business interruption or product liability insurance at the time.
Most important facts for investors to verify
- Whether the company raised qualifying financing, and whether it repaid, extended or converted the notes due July 31 and December 31, 2018.
- Current cash runway, operating cash burn, accrued liabilities and any subsequent financing or dilution from notes, warrants, options or equity awards.
- Actual completion of testing and FDA submissions, regulatory pathway and timing; do not treat projected clearance or launch dates as assured.
- Developments and potential financial or operational impact of the PMT litigation, including any effect on key personnel or intellectual property.
- Progress remediating material weaknesses and maintaining the WARF and Mayo agreements, including required payments and milestones.
- Any updates to the going-concern assessment, product testing evidence, reimbursement prospects and commercial manufacturing readiness.